Integra LifeSciences (IART) Stock Price, News & Analysis

Company Overview

Integra LifeSciences (NASDAQ:IART) is a global medical technology company focused on regenerative technologies, neurosurgery and reconstructive surgery. Headquartered in Princeton, New Jersey, Integra develops, manufactures and markets medical devices and instruments that support critical surgical procedures across a range of clinical specialties. The company’s offerings aim to improve patient outcomes by leveraging advanced biomaterials and proprietary technologies.

Integra’s product portfolio includes dural repair solutions, soft tissue regeneration products, external cranial protection systems and instruments for minimally invasive spine and peripheral nerve surgeries. Key offerings include collagen-based matrix products for skin and wound care, synthetic dural substitutes for neuroprotective repair and specialized nerve conduits designed to facilitate peripheral nerve regeneration. Many of these products are used in hospitals, outpatient centers and reconstructive surgery clinics worldwide.

With operations spanning North America, Europe, Asia-Pacific and Latin America, Integra LifeSciences serves an extensive network of surgeons, hospitals and distribution partners. The company has grown through a combination of internal research and development initiatives and targeted acquisitions, including the addition of ACell’s regenerative tissue technologies and Codman Neurosurgery’s portfolio from Johnson & Johnson. These strategic expansions have enhanced Integra’s capabilities in biomaterials science and broadened its reach in key geographies.

Founded in 1989, Integra LifeSciences has built a reputation for innovation in surgical technologies and regenerative medicine. The company’s leadership team, led by Chief Executive Officer Peter Arduini, brings together expertise in medical device development, global commercialization and regulatory affairs. Integra continues to invest in clinical research and product development to address evolving surgical challenges and meet the needs of healthcare providers worldwide.

Key Stats

• Today's Range: $12.50 to $13.07
• 50-Day Range: $11.60 to $13.98
• 52-Week Range: $11.06 to $32.66
• Volume: 692,979 shs
• Average Volume: 971,324 shs
• Market Capitalization: $978.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.63
• Consensus Rating: Reduce

Integra LifeSciences Stock Analysis - MarketRank™

Integra LifeSciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 190th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.78, and is based on 2 buy ratings, 3 hold ratings, and 4 sell ratings.

Amount of Analyst Coverage

Integra LifeSciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 2.04%

Earnings Growth

Earnings for Integra LifeSciences are expected to grow by 2.04% in the coming year, from $2.45 to $2.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Integra LifeSciences is -33.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Integra LifeSciences is -33.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Integra LifeSciences has a PEG Ratio of 0.70. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Integra LifeSciences has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.17% of the float of Integra LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Integra LifeSciences has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Integra LifeSciences has recently increased by 8.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Integra LifeSciences does not currently pay a dividend.

Dividend Growth

Integra LifeSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.50

Percentage of Shares Shorted

10.17% of the float of Integra LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Integra LifeSciences has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Integra LifeSciences has recently increased by 8.99%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

Integra LifeSciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Integra LifeSciences this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for IART on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.54% of the stock of Integra LifeSciences is held by insiders.

Percentage Held by Institutions

84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IART Stock Analysis - Frequently Asked Questions

How have IART shares performed this year?

Integra LifeSciences' stock was trading at $22.68 on January 1st, 2025. Since then, IART stock has decreased by 44.5% and is now trading at $12.59.

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) issued its quarterly earnings results on Monday, May, 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by $0.02. The business's revenue was up 3.7% on a year-over-year basis.
Read the conference call transcript.

When did Integra LifeSciences' stock split?

Integra LifeSciences's stock split on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does Integra LifeSciences have any subsidiaries?

The following companies are subsidiaries of Integra LifeSciences: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and others.

Who are Integra LifeSciences' major shareholders?

Top institutional shareholders of Integra LifeSciences include Assenagon Asset Management S.A. (1.54%), Wedge Capital Management L L P NC (0.09%), Wealth Enhancement Advisory Services LLC (0.02%) and MassMutual Private Wealth & Trust FSB (0.01%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen, Raymond G Murphy, Lisa Evoli, Witte Jan De and Jeffrey Mosebrook.
View institutional ownership trends.

How do I buy shares of Integra LifeSciences?

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:IART
• CIK: 917520
• Web: www.integralife.com
• Phone: (609) 275-0500
• Fax: 609-750-4277
• Employees: 4,396
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Integra LifeSciences: $18.63
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +47.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.14
• P/E Growth: 0.7
• Net Income: -$6.94 million
• Net Margins: -1.78%
• Pretax Margin: -2.65%
• Return on Equity: 12.12%
• Return on Assets: 4.58%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 1.21
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $1.61 billion
• Price / Sales: 0.61
• Cash Flow: $4.45 per share
• Price / Cash Flow: 2.83
• Book Value: $20.03 per share
• Price / Book: 0.63

Miscellaneous

• Outstanding Shares: 77,710,000
• Free Float: 74,961,000
• Market Cap: $978.37 million
• Optionable: Optionable
• Beta: 1.15